Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL

BACKGROUND: The clinical application of TRAIL receptor agonists as a novel cancer therapy has been tempered by heterogeneity in tumour responses. This is illustrated in breast cancer, where TRAIL is cytotoxic in cell lines of mesenchymal origin but refractory in lines with an epithelial-like phenoty...

Descripción completa

Detalles Bibliográficos
Autores principales: French, Rhiannon, Hayward, Olivia, Jones, Samuel, Yang, William, Clarkson, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678708/
https://www.ncbi.nlm.nih.gov/pubmed/26667821
http://dx.doi.org/10.1186/s12943-015-0478-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678708/
https://www.ncbi.nlm.nih.gov/pubmed/26667821
http://dx.doi.org/10.1186/s12943-015-0478-y

Ejemplares similares